1. Bioavailability of99mTc-Ha-paclitaxel complex [99mTc-ONCOFID-P] in mice using four different administration routes
- Author
-
Antonio Rosato, Pasquale Boccaccio, Nikolay Uzunov, Davide Camporese, Anna Nadali, Laura Meléndez-Alafort, Mattia Riondato, Ulderico Mazzi, and Alessandra Banzato
- Subjects
Biodistribution ,Organic Chemistry ,Pharmacology ,Biochemistry ,Analytical Chemistry ,Bioavailability ,chemistry.chemical_compound ,chemistry ,Paclitaxel ,Pharmacokinetics ,Oral administration ,Drug Discovery ,Hyaluronic acid ,Distribution (pharmacology) ,Radiology, Nuclear Medicine and imaging ,Spectroscopy ,Sodium gluconate - Abstract
Paclitaxel, an anti-tumour drug, shows good results against breast and ovarian cancer. However, its therapeutic response is associated with toxic side-effects caused by the agent used to dissolve it. Recently paclitaxel was linked to the linear polysaccharide hyaluronic acid (HA), showing good solubility, stabilization, localization and a reduction of cytotoxic side-effects. To study potential therapeutic applications, HA-paclitaxel bioconjugate (ONCOFID-P) was labelled with 99mTc by the addition of 99mTc-pertechnetate, SnCl2 and sodium gluconate. The reaction mixture was incubated for 90 min at 65°C and purified by size exclusion chromatography. The obtained 99mTc-ONCOFID-P had 100% radiochemical purity and was stable in a phosphate buffer dilution 1:100 for 6 h at 37°C. 99mTc-ONCOFID-P bioavailability studies were carried out in healthy mice using four different administration pathways. The analysis showed that after intravenous administration more than 80% of the injected radiopharmaceutical was found in liver and spleen. Intraperitoneal, intravesical and oral administrations showed that all the 99mTc-ONCOFID-P remained at the administration site. These results demonstrate that ONCOFID-P administered intravenously could be used for liver metastasis therapy due to its high physiological and receptor-specific liver uptake, while intravesical, intraperitoneal and oral administration of ONCOFID-P could be used for local treatment of superficial cancers. Copyright © 2006 John Wiley & Sons, Ltd.
- Published
- 2006
- Full Text
- View/download PDF